The peptide oxytocin receptor antagonist Atosiban improved social behavior, reduced anxiety, and decreased repetitive behaviors in a female rat model of autism — challenging the assumption that more oxytocin always helps ASD.
OXT signaling elevated in female autism modelBoth oxytocin and its receptor were overexpressed in the hippocampus and prefrontal cortex of VPA-induced autistic female rats — the opposite of the expected deficit
What the researchers found
In a valproic acid (VPA)-induced female rat model of autism, researchers found that oxytocin and its receptor were overexpressed in the hippocampus and prefrontal cortex — the opposite of what is typically assumed in autism research, where oxytocin deficiency is the prevailing narrative. Administering exogenous oxytocin to healthy female rats actually triggered autism-like behaviors.
Critically, the oxytocin receptor antagonist Atosiban (a peptide drug) significantly improved multiple autism-like deficits in VPA-exposed female rats, including social interaction impairment, anxiety, and repetitive stereotypical behaviors. Atosiban also improved synaptic plasticity that had been impaired by VPA exposure.
Why it matters
Most autism research has focused on males and on the idea that oxytocin supplementation helps social behavior. This study flips that narrative for females, suggesting that in female autism, oxytocin signaling may actually be excessive — and blocking it with a peptide antagonist could be therapeutic. This has significant implications for sex-specific treatment approaches to ASD.
How the study worked
Researchers used a VPA-induced autism model in female rats, measuring oxytocin and oxytocin receptor expression in the hippocampus and prefrontal cortex. They tested two interventions: intranasal exogenous oxytocin in wild-type females (to see if excess OXT causes autism-like behavior) and the oxytocin receptor antagonist Atosiban in VPA-exposed females (to see if blocking OXT signaling improves symptoms). Behavioral tests assessed social interaction, anxiety, and stereotypical behaviors, while synaptic plasticity was measured in brain tissue.
Who was studied
Female Sprague-Dawley rats (VPA-induced autism model)
What this study cannot tell us
This is an animal study using a chemically induced autism model in rats, which may not fully recapitulate human ASD. The VPA model represents only one potential pathway to autism. Results in female rats may not directly translate to female humans with ASD. Specific dosing, sample sizes, and effect magnitudes are not detailed in the abstract.
How to read the evidence
This is a preliminary-grade animal study using a chemically induced autism model in female rats. While the findings are provocative and internally consistent, they require replication and human studies before drawing clinical conclusions.
When this study was published
Published in 2024, this is recent research contributing to the growing focus on sex differences in autism biology and treatment.
The bigger picture
Autism research has been heavily male-biased, and the oxytocin-as-treatment paradigm is largely based on male data. This study is part of a growing recognition that female ASD may have distinct biological mechanisms. If excess oxytocin signaling contributes to female autism, it would represent a paradigm shift requiring completely different therapeutic strategies — potentially repurposing existing peptide drugs like Atosiban.
Questions still open
- Does the oxytocin excess pattern seen in this female rat model also occur in human females with ASD?
- Could Atosiban, which is already approved for use in humans as a tocolytic agent, be repurposed for clinical trials in female ASD patients?
- What mechanisms cause oxytocin signaling to be elevated rather than reduced in female autism, and does this relate to estrogen-oxytocin interactions?
Common questions
What is Atosiban and is it already used in medicine?
Why might oxytocin treatment work differently in males vs. females with autism?
Read the original research
Administration of Atosiban, an oxytocin receptor antagonist, ameliorates autistic-like behaviors in a female rat model of valproic acid-induced autism.
Behavioural brain research, 469, 115052
Citation
Liu, Chunhua; Guo, Zhengyang; Pang, Jiyi; Zhang, Yuying; Yang, Zhuo; Cao, Jianting; Zhang, Tao. (2024). Administration of Atosiban, an oxytocin receptor antagonist, ameliorates autistic-like behaviors in a female rat model of valproic acid-induced autism.. Behavioural brain research, 469, 115052. https://doi.org/10.1016/j.bbr.2024.115052